Spectral AI Inc. Takes Bold Step Towards Transforming Burn Care

Spectral AI Inc. . (NASDAQ-MDAI), a Dallas-based predictive AI company, has commenced enrollment in a pivotal study to validate the effectiveness of their revolutionary DeepView AI® technology for burn injuries. This study marks a significant milestone on their journey towards seeking FDA marketing authorization for the burn indication in 2025.
With a focus on medical diagnostics for faster and more accurate treatment decisions in wound care, Spectral AI is at the forefront of innovation. Their DeepView AI® system, powered by proprietary imaging technology, aims to assess burn size and healing potential with unparalleled accuracy and speed. By predicting burn wound healing potential on the first day of injury, Spectral AI's technology has the potential to revolutionize burn care pathways and enable early treatment decisions.
The pivotal study will be conducted in burn centers and emergency departments across the United States, enrolling both adult and pediatric patients. Led by Dr. Jeffrey C. Carter, a highly experienced investigator, the study aims to deepen our understanding of how DeepView AI® can transform burn care while improving patient outcomes. This critical research will contribute to enhancing its preparedness for unforeseen emergencies, such as Burn Mass Casualty Incidents.
Spectral AI is utilizing significant government funding of $251 million since 2019 to validate DeepView for burn indication, as well as advancing other clinical indications like diabetic foot ulcers.